Equities

Formosa Pharmaceuticals Inc

6838:TAI

Formosa Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (TWD)38.95
  • Today's Change0.05 / 0.13%
  • Shares traded167.20k
  • 1 Year change-22.87%
  • Beta--
Data delayed at least 20 minutes, as of Nov 22 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in TWDIncome statement in TWDView more

Year on year Formosa Pharmaceuticals Inc grew revenues 2,270.49% from 1.32m to 31.17m while net income improved from a loss of 406.27m to a smaller loss of 321.96m.
Gross margin84.63%
Net profit margin-145.95%
Operating margin-142.99%
Return on assets--
Return on equity--
Return on investment--
More ▼

Cash flow in TWDView more

In 2023, Formosa Pharmaceuticals Inc increased its cash reserves by 43.90%, or 117.37m. Cash Flow from Financing totalled 999.88m or 3,207.61% of revenues. In addition the company used 196.04m for operations while cash used for investing totalled 676.21m.
Cash flow per share-1.18
Price/Cash flow per share--
Book value per share10.62
Tangible book value per share8.30
More ▼

Balance sheet in TWDView more

Formosa Pharmaceuticals Inc uses little debt in its capital structure as supported by a debt to capital ratio of 1.67%.
Current ratio9.31
Quick ratio--
Total debt/total equity0.017
Total debt/total capital0.0167
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.